Recent from talks
Enantiopure drug
Knowledge base stats:
Talk channels stats:
Members stats:
Enantiopure drug
An enantiopure drug is a pharmaceutical available in one specific enantiomeric form. Most biomolecules (proteins, sugars, etc.) are present in only one of many chiral forms, so different enantiomers of a chiral drug molecule bind differently (or not at all) to target receptors.
The use of a drug with a single enantiomer intends to make it more effective. One enantiomer of a drug may have a desired beneficial effect while the other may cause serious and undesired side effects, or sometimes even beneficial but entirely different effects. The desired enantiomer of a given drug is known as the eutomer while the undesired enantiomer is known as the distomer. When equal amounts of both enantiomers are found in a mixture, the mixture is known as a racemic mixture. If a mixture for a drug does not have a 1:1 ratio of its enantiomers it is a candidate for an enantiopure drug.
Advances in industrial chemical processes have made it economical for pharmaceutical manufacturers to take drugs that were originally marketed as a racemic mixture and market the individual enantiomers, either by specifically manufacturing the desired enantiomer or by resolving a racemic mixture. On a case-by-case basis, the U.S. Food and Drug Administration (FDA) has allowed single enantiomers of certain drugs to be marketed under a different name than the racemic mixture. Also case-by-case, the United States Patent Office has granted patents for single enantiomers of certain drugs. The regulatory review for marketing approval (safety and efficacy) and for patenting (proprietary rights) is independent, and differs country by country.
In 1848, Louis Pasteur became the first scientist to discover chirality and enantiomers while he was working with tartaric acid. During the experiments, he noticed that there were two crystal structures produced but these structures looked to be non-superimposable mirror images of each other; this observation of isomers that were non-superimposable mirror images became known as enantiomers. A couple years later, in 1857, Pasteur then discovered enantioselectivity when he noticed that the two enantiomer structures he had previously discovered metabolized at much different speeds. This suggested that one configuration was preferred over the other in vivo. As organic chemistry knowledge became more advanced, the discovery of enantioselectivity was used in the creation of enantiopure drugs.
Chirality can be observed when the geometric properties of an object is not superimposable with its mirror image. Two forms of a molecule are formed (both mirror images) from a chiral carbon, these two forms are called enantiomers.
The formation of an enantiopure drug results from the separation of the enantiomers of a chiral drug. This separation was prompted when it was found that each enantiomer of a molecule can have different effects when used as pharmaceuticals. This is because the body is very chiral selective, reacting to each enantiomer differently and therefore producing different pharmaceutical effects.
Before a drug of a pure enantiomer can be formed, the two enantiomers must first be separated and tested. Three main techniques are used for this separation: capillary gas chromatography, high performance liquid chromatography, and capillary electrophoresis. Other techniques such as chiral crystallization, enzyme-based kinetic separation, and enantioselective synthesis are also used.
The body of living organisms are composed of many enantiopure chiral substances. For example, amino acids that make up the proteins in the body have the same configuration, L-absolute configuration. Because of this specificity, vital processes such as constructing proteins, rely on stereoselectivity to ensure that out of all the potential enantiomers available, the body is utilizing the correct enantiopure compound.
Hub AI
Enantiopure drug AI simulator
(@Enantiopure drug_simulator)
Enantiopure drug
An enantiopure drug is a pharmaceutical available in one specific enantiomeric form. Most biomolecules (proteins, sugars, etc.) are present in only one of many chiral forms, so different enantiomers of a chiral drug molecule bind differently (or not at all) to target receptors.
The use of a drug with a single enantiomer intends to make it more effective. One enantiomer of a drug may have a desired beneficial effect while the other may cause serious and undesired side effects, or sometimes even beneficial but entirely different effects. The desired enantiomer of a given drug is known as the eutomer while the undesired enantiomer is known as the distomer. When equal amounts of both enantiomers are found in a mixture, the mixture is known as a racemic mixture. If a mixture for a drug does not have a 1:1 ratio of its enantiomers it is a candidate for an enantiopure drug.
Advances in industrial chemical processes have made it economical for pharmaceutical manufacturers to take drugs that were originally marketed as a racemic mixture and market the individual enantiomers, either by specifically manufacturing the desired enantiomer or by resolving a racemic mixture. On a case-by-case basis, the U.S. Food and Drug Administration (FDA) has allowed single enantiomers of certain drugs to be marketed under a different name than the racemic mixture. Also case-by-case, the United States Patent Office has granted patents for single enantiomers of certain drugs. The regulatory review for marketing approval (safety and efficacy) and for patenting (proprietary rights) is independent, and differs country by country.
In 1848, Louis Pasteur became the first scientist to discover chirality and enantiomers while he was working with tartaric acid. During the experiments, he noticed that there were two crystal structures produced but these structures looked to be non-superimposable mirror images of each other; this observation of isomers that were non-superimposable mirror images became known as enantiomers. A couple years later, in 1857, Pasteur then discovered enantioselectivity when he noticed that the two enantiomer structures he had previously discovered metabolized at much different speeds. This suggested that one configuration was preferred over the other in vivo. As organic chemistry knowledge became more advanced, the discovery of enantioselectivity was used in the creation of enantiopure drugs.
Chirality can be observed when the geometric properties of an object is not superimposable with its mirror image. Two forms of a molecule are formed (both mirror images) from a chiral carbon, these two forms are called enantiomers.
The formation of an enantiopure drug results from the separation of the enantiomers of a chiral drug. This separation was prompted when it was found that each enantiomer of a molecule can have different effects when used as pharmaceuticals. This is because the body is very chiral selective, reacting to each enantiomer differently and therefore producing different pharmaceutical effects.
Before a drug of a pure enantiomer can be formed, the two enantiomers must first be separated and tested. Three main techniques are used for this separation: capillary gas chromatography, high performance liquid chromatography, and capillary electrophoresis. Other techniques such as chiral crystallization, enzyme-based kinetic separation, and enantioselective synthesis are also used.
The body of living organisms are composed of many enantiopure chiral substances. For example, amino acids that make up the proteins in the body have the same configuration, L-absolute configuration. Because of this specificity, vital processes such as constructing proteins, rely on stereoselectivity to ensure that out of all the potential enantiomers available, the body is utilizing the correct enantiopure compound.